UnitedHealth Group Incorporated

The stock remains in a long-term uptrend, trading well above its 200-day moving average and not far from its 52-week high. That keeps the regime constructive, though the recent pullback from the peak suggests the move is still digesting a sharp prior advance rather than breaking down.

Street sentiment is constructive: the consensus sits at Buy, with 43 Buys, 7 Holds, and 2 Sells. The average target has been lifted into the mid-$450s, and recent revisions have skewed higher, with multiple firms raising targets into the $470-$485 range.

Momentum into the next print is solid after UNH beat EPS by 31.0% last quarter and 9.5% the quarter before. Full-year expectations still point to higher earnings, with next-year EPS estimates around 21.0 versus 13.27 TTM, so shareholders should watch whether margin and utilization trends support that step-up.

No notable discretionary insider buying or selling. Recent filings are dominated by director and officer award grants, which read as routine compensation activity rather than a directional signal.

Profitability is steady, not flashy: operating margin is 8.05% and net margin is 2.68%, with ROE at 12.18%. Growth is modest at 2.0% revenue growth and 0.7% earnings growth year over year, while free cash flow remains strong at $23.3 billion and FCF yield at 6.06%.

UNH still screens as a premium managed-care franchise with scale across UnitedHealthcare and Optum, which supports resilience versus smaller peers. The valuation is not cheap at 25.91x earnings, but it sits alongside elevated targets and a market cap near $384.5 billion.